According to Zacks, Puma Biotechnology (PBYI) may be undervalued, as it currently holds a Zacks Rank of #2 (Buy) and an 'A' grade for Value. PBYI's PEG ratio of 1.38 is below its industry average of 2.51, its P/B ratio of 1.66 is also below its industry average of 2.84, and its P/CF ratio of 3.28 is significantly lower than the industry average of 7.97, suggesting a potentially strong cash outlook relative to its price.
Puma Biotechnology (PBYI) is highlighted as a potentially undervalued investment opportunity, currently holding a Zacks Rank of #2 (Buy) and an 'A' grade for Value. The company's Price/Earnings to Growth (PEG) ratio stands at 1.38, notably lower than its industry's average of 2.51, suggesting its stock price may not fully reflect its expected earnings growth rate. This PEG ratio is also at the low end of its 12-month range (1.38-1.46). Further supporting the undervaluation thesis, PBYI's Price-to-Book (P/B) ratio is 1.66, which is considerably more attractive than the industry average of 2.84 and near its 12-month low of 1.40. Additionally, the company's Price-to-Cash Flow (P/CF) ratio of 3.28 is substantially below the industry average of 7.97, indicating a strong operating cash flow relative to its valuation and also near its recent low of 2.76. These valuation metrics, combined with a positive earnings outlook implied by its Zacks Rank, suggest PBYI may represent a compelling value proposition for investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
Positive
Sentiment Score
0.85
Ticker Sentiment
